Provided herein are recombinant nucleic acid sequences derived from the C-terminal domain of the HIV-1 gp41 protein, and more specifically compositions and methods for using these epitopes to develop vaccine protection against HIV. Also provided here are monoclonal antibodies that specifically bind to these recombinant nucleic acid sequences derived from the C-terminal domain of the HIV-1 gp41 protein.